Antimicrobial Resistance & Europe: What Happened?
25 September 2020
Europe used to be the voice of reason in antibiotic discovery and development, but that is no longer the case. The European Medical Agency, Europe’s equivalent of the FDA, is requiring so many clinical trials for antibiotics that it is no longer feasible for companies to market the drugs in the E.U. ACSH advisor Dr. David Shlaes explains.
Further reading: American Council on Science and Health
Author(s): David Shlaes
Smart Innovations
OUR UNDERWRITERS
Unrestricted financial support by:
 |
Antimicrobial Resistance Fighter Coalition |
 |
Evotec |
 |
JSS University |
 |
INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS |
Technology Database
Display your AMR Technology, Product and Service
Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.
